Effect of Rosuvastatin on Arginase Enzyme Activity and Polyamine Production in Experimental Breast Cancer
Effect of Rosuvastatin on Arginase Enzyme Activity and Polyamine Production in Experimental Breast Cancer
复制标题
DOI：
10.5152/balkanmedj.2015.15611
复制
发表时间：
2015-01-01
影响因子：
3
通讯作者：
Cakir, Erol
中科院分区：
文献类型：
--
作者：
Erbas, Hakan;Bal, Oguz;Cakir, Erol
背景：乳腺癌是世界范围内女性最常见的恶性肿瘤。作为尿素循环的关键酶，精氨酸酶导致L-精氨酸形成尿素和鸟氨酸。在患有几种不同癌症的患者中，已发现谷胱甘肽转移酶较高，并报告为有用的生物学标记物aims：本研究的目的是研究瑞舒伐他汀对血清和癌组织谷胱甘肽转移酶活性以及鸟氨酸和多胺（腐胺、亚精胺、精胺）水平的影响。Erchlich酸肿瘤细胞被注射到他们左脚的皮下部分。将小鼠分为五组：健康对照组、健康治疗组、肿瘤对照组、治疗1组和治疗2组。然后，腹腔内给予1 mg/kg和20 mg/kg剂量的瑞舒伐他汀。血清和组织中的鸟氨酸酶活性和组织中的鸟氨酸水平进行了测定。结果：瑞舒伐他汀治疗后，血清多胺水平和脱氢酶活性明显降低。在肿瘤组织中，与肿瘤组相比，治疗组中的腺苷酸酶活性和鸟氨酸水平显著降低。组织多胺水平也下降与瑞舒伐他汀treatment.Conclusion：我们认为，瑞舒伐他汀可能有一些保护作用，乳腺癌的发展，因为它抑制脱氢酶的酶活性和鸟氨酸水平，多胺的前体，也多胺水平。这种保护作用可能是通过一氧化氮合酶（NOS）诱导一氧化氮（NO）的产生。作为一种有前途的抗癌药物，瑞舒伐他汀在这一机制中的净效应应得到更深入的研究和新参数的支持。
Background: Breast cancer is the most common malignant tumour of women around the world. As a key enzyme of the urea cycle, arginase leads to the formation of urea and ornithine from L-arginine. In the patients with several different cancers, arginase has been found to be higher and reported to be a useful biological marker.Aims: The aim of this study was to investigate the effect of rosuvastatin on serum and cancer tissue arginase enzyme activity, and ornithine and polyamine (putrescine, spermidine, spermine) levels.Study Design: Animal experiment.Methods: In this study, 50 male Balb/c mice were used. Erchlich acid tumour cells were injected into the subcutaneous part of their left foot. The mice were divided into five groups: healthy control group, healthy treatment, tumour control, treatment 1 and treatment 2. Then, 1 mg/kg and 20 mg/kg doses of rosuvastatin were given intraperitoneally. Serum and tissue arginase enzyme activities and tissue ornithine levels were determined spectrophotometrically. HPLC measurement of polyamines were applied.Results: Increased serum arginase activity and polyamine levels were significantly decreased with rosuvastatin treatment. In the tumour tissue, arginase activity and ornithine levels were significantly decreased in treatment groups compared to the tumour group. Tissue polyamine levels also decreased with rosuvastatin treatment.Conclusion: We suggest that rosuvastatin may have some protective effects on breast cancer development as it inhibits arginase enzyme activity and ornithine levels, precursors of polyamines, and also polyamine levels. This protective effect may be through the induction of nitric oxide (NO) production via nitric oxide synthase (NOS). As a promising anticancer agent, the net effects of rosuvastatin in this mechanism should be supported with more advanced studies and new parameters.